文献速递生殖医学

预测低反应者IVF/ICSI中应停止使用高FSH剂量

Individualized ovarian stimulation in IVF/ICSI treatment: it is time to stop using high FSH doses in predicted low responders.
PubMed 文献 · Hum Reprod · 2020-01-01

本文讨论预测低反应者IVF/ICSI中高FSH起始剂量的个体化刺激策略,指出高剂量虽略增获卵数(平均多1-2个),但未证明提高活产概率(风险差-0.02,95%CI -0.11至0.06),并分析横断面数据因果误读及去实施困难。

要点

  • 高FSH剂量较标准剂量平均多获1-2个卵母细胞,但活产概率无获益(风险差-0.02,95%CI -0.11至0.06)。
  • 横断面研究中获卵数与活产概率正相关被误读为直接因果关系,不应据此指导FSH剂量。
  • 去实施高FSH剂量策略面临中间结局优先(如周期取消)及确认偏倚或救援偏倚等解释偏倚的困难。

核心结论

  • 高FSH剂量可能并未实际提高预测低反应者IVF/ICSI治疗的活产概率。
  • 直接将横断面数据用于指导临床FSH剂量存在缺陷。

研究设计与样本

  • 本文为论述性文章,引用多项随机对照试验及横断面研究进行论证。

主要发现

  • 高剂量组较标准剂量组平均多1-2个卵母细胞,但活产概率无获益(风险差-0.02,95%CI -0.11至0.06)。
  • 横断面研究中获卵数与活产概率的正相关被解释为直接因果 relation。

关键数值与推荐

  • 高剂量与标准剂量组活产风险差为-0.02(95%CI -0.11至0.06)。
  • 高剂量组平均较标准剂量组多1-2个卵母细胞。

临床怎么用

  • 临床不应因相信「获卵越多越好」而给预测低反应者增加FSH起始剂量。
  • 需关注去实施高FSH剂量策略中中间结局优先及解释偏倚的问题。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In IVF/ICSI treatment, the FSH starting dose is often increased in predicted low responders from the belief that it improves the chance of having a baby by maximizing the number of retrieved oocytes. This intervention has been evaluated in several randomized controlled trials, and despite a slight increase in the number of oocytes-on average one to two more oocytes in the high versus standard dose group-no beneficial impact on the probability of a live birth has been demonstrated (risk difference, -0.02; 95% CI, -0.11 to 0.06). Still, many clinicians and researchers maintain a highly ingrained belief in 'the more oocytes, the better'. This is mainly based on cross-sectional studies, where the positive correlation between the number of retrieved oocytes and the probability of a live birth is interpreted as a direct causal relation. If the latter would be present, indeed, maximizing the oocyte number would benefit our patients. The current paper argues that the use of high FSH doses may not actually improve the probability of a live birth for predicted low responders undergoing IVF/ICSI treatment and exemplifies the flaws of directly using cross-sectional data to guide FSH dosing in clinical practice. Also, difficulties in the de-implementation of the increased FSH dosing strategy are discussed, which include the prioritization of intermediate outcomes (such as cycle cancellations) and the potential biases in the interpretation of study findings (such as confirmation or rescue bias).

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Leijdekkers JA, Torrance HL, Schouten NE, et al. Individualized ovarian stimulation in IVF/ICSI treatment: it is time to stop using high FSH doses in predicted low responders. Hum Reprod. 2020. PMID: 31838515. doi:10.1093/humrep/dez184

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。